文献速递前列腺癌

新诊断寡转移性前列腺癌:当前争议与未来进展

Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments.
PubMed 文献 · Eur Urol Oncol · 2020-11-25

本文报告一名56岁新诊断寡转移性前列腺癌患者(cT3b cN1 cM1b,ISUP分级组3,低瘤负荷),在临床试验中接受ADT后行机器人辅助根治性前列腺切除及扩大盆腔淋巴结清扫,术后放疗及ADT维持。讨论聚焦分子影像、局部治疗和转移定向治疗三个开放问题。

要点

  • 分子影像(如PSMA PET/CT)是否改变治疗策略尚存争议。
  • 转移背景下局部治疗(前列腺切除)的作用需进一步明确。
  • 转移定向治疗是否适用于新诊断寡转移患者仍待研究。

核心结论

  • 新诊断寡转移性前列腺癌的最佳管理仍具挑战,分子影像、局部治疗和转移定向治疗是重要开放问题。

研究设计与样本

  • 病例报告:56岁男性,新诊断cT3b cN1 cM1b、ISUP分级组3、低瘤负荷(CHAARTED标准)、低风险(LATITUDE标准)前列腺癌,在临床试验中接受ADT后行机器人辅助根治性前列腺切除及扩大盆腔淋巴结清扫(ypT3b pN1 R1),术后放疗(前列腺床70Gy、盆腔淋巴结54Gy、耻骨51Gy),ADT计划36个月。

主要发现

  • 常规影像显示左侧两个肿大淋巴结靠近髂外血管,左侧耻骨15mm可疑转移灶,骨扫描确认无其他转移。
  • 术后病理为ypT3b pN1 R1,目前ADT治疗中(剩余6个月),最近PSA不可测。

临床怎么用

  • 对于新诊断寡转移性前列腺癌,可考虑在临床试验框架下进行局部治疗联合ADT及术后放疗。
  • 需个体化评估分子影像(如PSMA PET/CT)对分期和治疗决策的影响。

局限性

  • 单例病例报告,结论不能推广至所有寡转移性前列腺癌患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This report presents a 56-yr-old man in good general health status, newly diagnosed with a cT3b, cN1, cM1b, International Society of Urological Pathology grade group 3, low-volume (CHAARTED criteria), low-risk (LATITUDE criteria) metastatic prostate cancer. Staging was performed with conventional imaging: a computed tomography (CT) scan showed the presence of two enlarged lymph nodes on the left, close to the external iliac vessels. In addition, a suspicious 15-mm metastatic lesion was detected in the left pubic bone. This lesion was confirmed on the bone scan, without further metastatic lesions. In the context of a clinical trial, after an initial course of androgen deprivation therapy (ADT), the patient was treated with robot-assisted radical prostatectomy and extended pelvic lymph node dissection (histopathological examination: ypT3b pN1 R1). Postprostatectomy radiation therapy was delivered on prostatic bed (70Gy), pelvic lymph node area (54Gy), and pubic bone (51Gy). ADT was scheduled for a total period of 36 mo. Currently, the patient is still receiving ADT, which will be completed within 6 mo. The last prostate-specific antigen level was undetectable. The discussion is focused on the following three open questions: (1) Would molecular imaging (eg, prostate-specific membrane antigen positron emission tomography/CT) change the therapeutic approach to the patient? (2) Is there a role for local treatment in the metastatic setting? (iii) Should metastasis-directed therapy be considered for this patient? PATIENT SUMMARY: The optimal management of patients newly diagnosed with oligometastatic prostate cancer remains challenging. The fields of staging with modern imaging and therapy with novel treatment options are evolving rapidly. In particular, the role of a prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging, the impact of a local treatment on the prostate, and the effect of direct therapies on the metastases represent important open questions in this intriguing field.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Fossati N, Giannarini G, Joniau S, et al. Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments. Eur Urol Oncol. 2020. PMID: 33249083. doi:10.1016/j.euo.2020.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。